Clinical Features of Scleritis Across the Asia-Pacific Region

Ocul Immunol Inflamm. 2019;27(6):920-926. doi: 10.1080/09273948.2018.1484496. Epub 2018 Jun 28.

Abstract

Purpose: To examine the spectrum of scleritis in four tertiary institutions across the Asia-Pacific. Methods: Clinical records from 354 patients were reviewed from centers in Australia, Singapore, and India, excluding those with insufficient data (n = 24). Results: Indian patients presented younger (41.5 ± 13.4 years) than Australians (50.8 ± 17.5) and Singaporeans (48.6 ± 15.9), with fewer women (49% vs 62%/57%). Diffuse disease was universally most common. Autoimmune and infectious disease proportions were similar in Australia (31%/10.3%) and Singapore (27.5%/8.3%) but reversed in India (8.3%/30%). Necrotizing scleritis was most frequently associated with infection (27.3%). Presumed ocular tuberculosis accounted for 75% of infectious cases in India. Posterior scleritis had the highest complication rate (82.4%) and immunosuppressants used per patient (0.98 ± 0.31 95% CI). Conclusions: Clinical presentations of scleritis vary across the Asia-Pacific, particularly in endemic regions for tuberculosis such as India, where it affects younger men with a predominance of nodular and infectious disease.

Keywords: Asia-Pacific; autoimmune scleritis; diffuse anterior scleritis; infective scleritis; necrotizing anterior scleritis; nodular anterior scleritis; posterior scleritis; scleritis.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Asian People / ethnology
  • Australia / epidemiology
  • Child
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • India / epidemiology
  • Male
  • Middle Aged
  • Retrospective Studies
  • Scleritis / diagnosis
  • Scleritis / drug therapy
  • Scleritis / epidemiology*
  • Sex Distribution
  • Singapore / epidemiology
  • Tertiary Care Centers / statistics & numerical data*
  • Visual Acuity
  • Young Adult

Substances

  • Immunosuppressive Agents